Search

Repeated vaccination does not appear to impact upon influenza vaccine effectiveness against hospitalization with confirmed influenza

These findings reinforce current recommendations for annual influenza vaccination, particularly those at greatest risk of influenza disease.

Influenza hospitalizations in Australian children

NIP has seen poor vaccine impact, related to recent vaccine safety concerns.

Birth outcomes for Australian mother-infant pairs who received an influenza vaccine during pregnancy, 2012-2014: The FluMum study

We assessed the safety of receiving an influenza vaccination during any trimester of pregnancy with respect to preterm births and infant birthweight.

Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2015: the Influenza Complications Alert Network

This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2015 influenza season

Geogenic PM10 exposure exacerbates responses to influenza infection

This study aimed to determine whether chronic, low-dose exposure to geogenic particulate matter <10μm diameter (PM10) exacerbates viral infections of the...

Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015

This paper reports the results from the safety surveillance of influenza vaccines in children in Australia, in 2015.

Comparison of text-messaging to voice telephone interviews for active surveillance of adverse events following immunisation.

This study was designed to compare data collected via SMS and telephone for the purposes of monitoring vaccine safety.

FluMum: A prospective cohort study of mother-infant pairs assessing the effectiveness of maternal influenza vaccination in revention of influenza

Evidence is emerging of benefit to the infant with respect to preventing influenza infection in the first 6 months of life. The FluMum study aims to...

Pandemic clinical case definitions are non-specific

During the early phases of the 2009 pandemic, subjects with influenza-like illness only had laboratory testing specific for the new A(H1N1)pdm09 virus.

Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial

Aboriginal children living in remote communities are at high risk of early and persistent otitis media. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are primary pathogens. Vaccines with potential to prevent early OM have not been evaluated in this population. We compared immunogenicity (ELISA and opsonophagocytic activity) of a combination of Synflorix™ (PHiD-CV10, 10 serotypes and protein D of NTHi) and Prevenar13™ (PCV13, 10 serotypes plus 3, 6A, and 19A), with recommended schedules.